Results 51 to 60 of about 4,735 (197)

Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia

Case Reports in Dermatology, 2013
Introduction: Frontal fibrosing alopecia (FFA) is a scarring alopecia characterized by progressive recession of the frontotemporal hairline. Current treatment is aimed at stopping progression, and the combination of dutasteride and pimecrolimus is the ...
Irma Margarita Pérez-Rodríguez, Martha Elena García-Melendez, Kristian Eichelmann, Osvaldo Vázquez-Martínez, Jorge Ocampo-Candiani   +4 more
doaj   +1 more source

Real‐World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With PSA Level of 4–10 ng/mL

The Prostate, Volume 86, Issue 12, Page 1258-1262, September 2026.
ABSTRACT Background Prostate‐specific antigen (PSA) is a widely used prostate cancer marker; however, its use is limited by its low specificity. Novel biomarkers are being explored to avoid unnecessary biopsies. A new prostate cancer marker, S2,3PSA, became eligible for insurance coverage in February 2024.
Jun Furumido, Sho Nonoyama, Chika Hoshi (Hosokawa), Shogo Aizawa, Nariaki Ozaki, Takuto Morita, Akihiro Yamashita, Issei Tsunemi, Ryo Kato, Kanta Hori, Naohiko Shimoda   +10 more
wiley   +1 more source

Dutasterid [PDF]

pharma-kritik, 2004
Ein zweiter 5alpha-Reduktasehemmer zur Behandlung der benignen Prostatahyperplasie. Dutasterid hat eine ungewöhnlich lange Halbwertszeit und erscheint nach bisherigem Wissen als ähnlich wirksam wie Finasterid. Die Symptome der Prostathyperplasie werden von diesen Substanzen eher weniger gut gelindert als von Alphablockern.
openaire   +1 more source

Omega Fatty Acids in Hair Loss Disorders: A Scoping Review of Preclinical and Clinical Evidence

Journal of Cosmetic Dermatology, Volume 25, Issue 9, September 2026.
ABSTRACT Background Omega fatty acids, including polyunsaturated omega‐3 and omega‐6 fatty acids (PUFAs) and monounsaturated omega‐9 fatty acids, regulate inflammation, cellular signaling, and tissue homeostasis, and may influence hair follicle biology and hair growth.
Nana‐Hawwa Abdul‐Rahman, Jacqueline D. Wang, Miriam Motlak, Gerardo Guiltarte, Reethi S. Padmanabhan, Ellen T. Lee, Sonal Choudhary   +6 more
wiley   +1 more source

Contact Sensitization in Patients With Frontal Fibrosing Alopecia: Patch Test Results With an Extended Baseline Series in Consecutive Patients

Contact Dermatitis, Volume 95, Issue 2, Page 192-199, August 2026.
Sensitization to propolis, shellac and gallate mix is FFA‐associated, but its relevance is largely unknown. Sensitization to salicylates is frequent and associated with symptoms of intolerance to sun exposure or sunscreens. No significant improvement by allergen avoidance is identified.
María‐Antonia Pastor‐Nieto, María Elena Gatica Ortega, Anna María Giménez‐Arnau, Tatiana Sanz‐Sánchez, Pedro Mercader García, Inmaculada Ruíz‐González, Gemma Melé‐Ninot, Pablo Chicharro, Paloma Sánchez‐Pedreño, Marina de Vega, Miguel Ángel Gallego Descalzo, Leopoldo Borrego   +11 more
wiley   +1 more source

The role of dutasteride in reducing complications of transurethral resection of prostate [PDF]

Al Ameen Journal of Medical Sciences
Purpose: To evaluate the superiority of dutasteride over a placebo in patients having their prostate removed during transurethral resection for benign prostate hyperplasia. Material and Methods: The study included a total of 30 patients, with 15 patients
Shyamal Shah, P. Periasamy
doaj  

Efficacy and Safety of Microneedling Combined With Mesotherapy for Androgenic Alopecia: A Retrospective Study Comparing Four Treatment Protocols

Health Science Reports, Volume 9, Issue 7, July 2026.
ABSTRACT Background and Aims Androgenic alopecia (AGA) is a prevalent form of hair loss characterized by progressive miniaturization of hair follicles, significantly impacting patients’ self‐confidence and quality of life. Current FDA‐approved treatments demonstrate limited to moderate efficacy.
Elham Behrangi, Roya Zeinali, Paria Jafari, Zahra Nosrati, Azadeh Goodarzi   +4 more
wiley   +1 more source

Comparative Analysis of 3‐Year Reintervention Rates for Rezum vs. UroLift: A TriNetX Study

International Journal of Urology, Volume 33, Issue 7, July 2026.
ABSTRACT Objectives Rezum and UroLift are minimally invasive treatments for benign prostatic hyperplasia (BPH), but long‐term comparative data remain limited. This study compared 3‐year reintervention rates between the two procedures using the TriNetX database.
Yu‐Cheng Lu, Allen W. Chiu, Chen‐Hsun Ho, Tzu‐Fu Huang, Yu‐Hsuan Shao   +4 more
wiley   +1 more source

Efficacy, safety, and adverse effects of finasteride and dutasteride in treating benign prostatic hyperplasia: A retrospective cohort study

Zanco Journal of Medical Sciences
Background and objective: Symptomatic benign prostatic hyperplasia (BPH) results in several symptoms including the lower urinary tract symptoms. Consequently, BPH may affect the bladder and finally the kidneys.
Wishyar Jamal Al-Bazzaz
doaj   +1 more source

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer

Journal of Translational Medicine, 2023
Background The incidence of bladder cancer (BCa) is approximately four times higher in men than in women. To develop effective BCa treatments, there is an urgent need to understand the differences in the BCa control mechanisms based on gender. Our recent
Jaekwon Seok, Hee Jeong Kwak, Yeonjoo Kwak, Moonjung Lee, Kyoung Sik Park, Aram Kim, Ssang-Goo Cho   +6 more
doaj   +1 more source